{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:53:25Z","timestamp":1790837605794,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Friedreich Ataxia (FRDA) is an autosomal recessive neurodegenerative disorder that causes gait and limb ataxia, dysarthria, and impaired vibratory sense, with cardiomyopathy being the predominant cause of death. There is no approved therapy, which results in the use of symptomatic treatments and the chronic support of physiotherapy. Dimethyl fumarate (DMF) is a fumaric acid ester used for the treatment of psoriasis and Multiple Sclerosis (MS). It induces Nrf2 <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>, and it increases frataxin in FRDA patient lymphoblasts, in mouse models, and in MS treated patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The aim of our study is to investigate if DMF can increase the expression of the <jats:italic>FXN<\/jats:italic> gene and frataxin protein and ameliorate <jats:italic>in-vivo<\/jats:italic> detectable measures of mitochondrial dysfunction in FRDA. The study is composed of a screening visit and two sequential 12-week phases: a core phase and an extension phase. During the first phase (core), patients will be randomly assigned to either the DMF or a placebo group in a 1:1 ratio. During the first week, patients will receive a total daily dose of 240 mg of DMF or placebo; from the second week of treatment, the dose will be increased to two 120 mg tablets BID for a total daily dose of 480 mg. During the second phase (extension), all patients will be treated with DMF. EudraCT number 2021-006274-23.<\/jats:p><\/jats:sec><jats:sec><jats:title>Endpoints<\/jats:title><jats:p>The primary endpoint will be a change in <jats:italic>FXN<\/jats:italic> gene expression level after 12 weeks of treatment. Secondary endpoints will be frataxin protein level, <jats:bold>c<\/jats:bold>ardiopulmonary exercise test outputs, echocardiographic measures, Nrf2 pathway and mitochondrial biogenesis gene expression, safety, clinical scales, and quality of life scales.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This is the first study aimed at exploring the ability of DMF, an already available treatment for MS and psoriasis, to correct the biological deficits of FRDA and potentially improve mitochondrial respiration <jats:italic>in-vivo<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnins.2023.1260977","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T17:32:55Z","timestamp":1694107975000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Rationale and protocol of a double-blind, randomized, placebo-controlled trial to test the efficacy, safety, and tolerability of dimethyl fumarate in Friedreich Ataxia (DMF-FA-201)"],"prefix":"10.3389","volume":"17","author":[{"given":"Chiara","family":"Pane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Maria","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Campanile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Coscetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Crisci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"D'Assante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Marsili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Puorro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cittadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sacc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/11533240-000000000-00000","article-title":"Dimethylfumarate for psoriasis","volume":"11","author":"Bovenschen","year":"2010","journal-title":"Am. J. Clin. Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1126\/science.1098991","article-title":"Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity","volume":"305","author":"Bulteau","year":"2004","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/mds.22660","article-title":"Comparison of three clinical rating scales in Friedreich ataxia (FRDA)","volume":"24","author":"B\u00fcrk","year":"2009","journal-title":"Mov. Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"key":"B5","unstructured":"Committee for Medicinal Products for Human Use (CHMP)2017"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/1531-8257(200011)15:6&lt;1255::AID-MDS1031&gt;3.0.CO;2-C","article-title":"Accuracy of clinical diagnostic criteria for Friedreich's ataxia","volume":"15","author":"Filla","year":"2000","journal-title":"Mov. Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1093\/eurheartj\/ehw180","article-title":"2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations","volume":"39","author":"Guazzi","year":"2018","journal-title":"Eur. Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/brain\/104.3.589","article-title":"Friedreich's ataxia: a clinical and genetic stud of 90 families with analysis of early diagnostic criteria and intrafamilial clustering of clinical features","volume":"104","author":"Harding","year":"1981","journal-title":"Brain"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0153574","DOI":"10.1371\/journal.pone.0153574","article-title":"Lymphoblast oxidative stress genes as potential biomarkers of disease, severity, and drug effect in Friedreich's Ataxia","volume":"11","author":"Hayashi","year":"2016","journal-title":"PLoS ONE"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1093\/hmg\/ddx167","article-title":"Dimethyl fumarate mediates Nrf2-dependent mitochondrial biogenesis in mice and humans","volume":"26","author":"Hayashi","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0217776","DOI":"10.1371\/journal.pone.0217776","article-title":"Dimethyl fumarate dosing in humans increases frataxin expression: a potential therapy for Friedreich ataxia","volume":"14","author":"Jasoliya","year":"2019","journal-title":"PLoS ONE"},{"key":"B13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jneuroim.2013.07.007","article-title":"Dimethyl fumarate regulates histone deacetylase expression in astrocytes","volume":"263","author":"Kalinin","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0140-6736(14)60382-2","article-title":"Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia","volume":"384","author":"Libri","year":"2014","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/brain\/awq386","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway","volume":"134","author":"Linker","year":"2011","journal-title":"Brain"},{"key":"B16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1365-2125.2004.02145.x","article-title":"Pharmacokinetics of oral fumarates in healthy subjects","volume":"58","author":"Litjens","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","article-title":"Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study)","volume":"89","author":"Lynch","year":"2021","journal-title":"Ann. Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/archneurol.2010.168","article-title":"A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia","volume":"67","author":"Lynch","year":"2010","journal-title":"Arch. Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjd.14947","article-title":"Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis:a randomized, double-blind, Fumaderm(\u00ae) - and placebo-controlled trial (BRIDGE)","volume":"176","author":"Mrowietz","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev.pharmtox.43.100901.140229","article-title":"Regulatory mechanisms controlling gene expression mediated by the antioxidant response element","volume":"43","author":"Nguyen","year":"2003","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s00415-018-8820-0","article-title":"Adult normative values for the PATA Rate Test","volume":"265","author":"Pane","year":"2018","journal-title":"J. Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e4253","DOI":"10.1371\/journal.pone.0004253","article-title":"Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia","volume":"4","author":"Paupe","year":"2009","journal-title":"PLoS ONE"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e001121","DOI":"10.1136\/bmjresp-2021-001121","article-title":"ARTP statement on cardiopulmonary exercise testing 2021","volume":"8","author":"Pritchard","year":"2021","journal-title":"BMJ Open Respir Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1474-4422(21)00027-2","article-title":"Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study","volume":"20","author":"Reetz","year":"2021","journal-title":"Lancet Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(16)30287-3","article-title":"Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study","volume":"16","author":"Reetz","year":"2016","journal-title":"Lancet Neurol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00403-010-1061-4","article-title":"Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients","volume":"302","author":"Rostami-Yazdi","year":"2010","journal-title":"Arch. Dermatol. Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e17627","DOI":"10.1371\/journal.pone.0017627","article-title":"A combined nucleic acid and protein analysis in friedreich ataxia","volume":"6","author":"Sacc\u00e0","year":"2011","journal-title":"PLoS ONE"},{"key":"B28","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/mds.26552","article-title":"Long-term effect of Epoetin alfa on clinical and biochemical markers in Friedreich Ataxia","volume":"31","author":"Sacc\u00e0","year":"2016","journal-title":"Mov. Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"6848","DOI":"10.1093\/hmg\/ddu408","article-title":"Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia","volume":"23","author":"Sahdeo","year":"2014","journal-title":"Hum. Mol. Genet."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2023.1260977\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T17:32:58Z","timestamp":1694107978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2023.1260977\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":29,"alternative-id":["10.3389\/fnins.2023.1260977"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2023.1260977","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"article-number":"1260977"}}